Key Highlights
- Azenta shares are trading down 7.66% at $45.16 versus a prior close of $48.90.
- The stock surged 20.80% on Wednesday after fiscal fourth quarter results.
- Non-GAAP Earnings Per Share were $0.28 against about $0.12 expected.
- Fiscal 2027 Revenue guidance is $648 million to $660 million.
- Jefferies raised its target to $52 from $44 with a Buy rating.
Azenta (NASDAQ:AZTA) is trading down 7.66% at $45.16, giving back part of Wednesday's 20.80% surge to $48.90. Fiscal fourth quarter results and a fiscal 2027 outlook above consensus drove that jump, which took the stock near a new 52-week high. Peer Adaptive Biotechnologies (NASDAQ:ADPT) is trading down 1.81%.
Quarter Beats Expectations
Fourth quarter revenue was $167 million, up 5% reported and 2% organic, against about $160 million expected. Non-GAAP earnings per share were $0.28 against roughly $0.11 to $0.12 expected, though part of the beat came from a Stock Compensation Reversal tied to the former chief executive. Adjusted EBITDA was $19.4 million.
Full-year revenue was $622 million, up 2% organic and above the high end of guidance.
Fiscal 2027 Outlook
Guidance calls for revenue of $648 million to $660 million, or 3% to 5% organic growth, above the roughly $639 million consensus. Adjusted EBITDA Margin should expand about 200 to 250 basis points, including about 100 basis points of dilution from the Elegen license and the SynPlexity acquisition. Free Cash Flow is expected to improve about 25% over fiscal 2026.
The first quarter is guided to organic growth of 3% to 4% and margin expansion of 100 to 150 basis points. Free cash flow is expected to be negative in the first quarter on Capital spending timing, restructuring and integration costs, then improve through the year.
Cash and Buybacks
Free cash flow was $12 million in the fourth quarter and $27 million for the year, below expectations on Working Capital and higher capital spending. Azenta ended with $506 million in cash and marketable securities and no debt. It repurchased 4.4 million shares for $118 million in fiscal 2026, with $132 million remaining on the authorization.
Multi-Omics Repositioning
Multi-Omics revenue fell 1% organically in the fourth quarter, while the sample management Business grew 4%. The October restructuring should save about $11 million annually, on top of about $7 million from earlier actions.
Analyst View
Jefferies raised its target to $52 from $44. Four of five analysts are bullish, with an average target of $45.60 and a range of $35 to $57.
First Half Execution Decides the Next Move
After a one-day gain of nearly 21%, the stock sits close to its average target. Investors will watch whether first quarter organic growth reaches the 3% to 4% range, whether cash flow turns positive after the first quarter and how Multi-Omics performs after the restructuring.
The pace of Buybacks against the $132 million left is another marker.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...